Overview

Study to Evaluate the Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Effects of Repeat Topical Application of BOS-356 in Subjects With Moderate to Severe Acne Vulgaris

Status:
Completed
Trial end date:
2020-11-11
Target enrollment:
Participant gender:
Summary
This study is being conducted to characterize the safety and tolerability of BOS-356 in adult participants with moderate to severe acne vulgaris following 14 days or 28 days of repeated topical application
Phase:
Phase 1
Details
Lead Sponsor:
Boston Pharmaceuticals